Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Both pharmacotherapeutic and psychosocial interventions have domenstrated efficacy for PTSD.
However, although these interventions can be helpful, many patients remain symptomatic
despite initial treatment. In this study, we will examine the relative efficacy of the
addition of paroxetine-CR compared to placebo for patients remaining symptomatic despite a
brief and intensive course of cognitive-behavioral therapy (CBT).